Table 1.
Baseline characteristics after matching.
| Variable | Systematic confirmatory biopsy (n=257) | MRI confirmatory biopsy* (n=257) | p-value | |
|---|---|---|---|---|
|
| ||||
| Clinical Characteristics | Median age, years (IQR) | 64 (58–69) | 61 (56–66) | <0.001 |
| Race, n (%) | 0.96 | |||
| White | 202 (78.6) | 204 (79.4) | ||
| Black | 22 (8.6) | 22 (8.6) | ||
| Other | 33 (12.8) | 31 (12.1) | ||
| Clinical T stage, n (%) | 0.3 | |||
| T1-T2a | 253 (98.4) | 248 (96.5) | ||
| T2b-T2c | 2 (0.8) | 3 (1.2) | ||
| Unknown | 2 (0.8) | 6 (2.3) | ||
| Median PSA prior to biopsy, ng/mL (IQR) | 5.3 (4.1–7.3) | 5.3 (4.2–7.7) | 0.4 | |
| Median prostate volume, cm3 (IQR) | 38.8 (29.8–52.3) | 38 (31–53) | 0.6 | |
| Median PSA density, (IQR) | 0.13 (0.09–0.20) | 0.14 (0.09–0.20) | 0.2 | |
|
| ||||
| Initial Biopsy Characteristics | Median number of cores, (IQR) | 12 (12–12) | 12 (12–12) | 0.02 |
| Median total tumor length, mm (IQR) | 2 (1–5) | 3 (1.5–6) | <0.001 | |
| Median maximum single core length, mm (IQR) | 1.5 (1–3) | 2.5 (1–4) | 0.001 | |
| Median number positive cores, (IQR) | 2 (1–2) | 2 (1–2) | 0.8 | |
| Grade Group, n (%) | 1 | |||
| 1 | 200 (77.8) | 200 (77.8) | ||
| 2 | 55 (21.4) | 55 (21.4) | ||
| 3 | 2 (0.78) | 2 (0.78) | ||
| 4–5 | 0 | 0 | ||
| Risk Group, n (%) | 0.9 | |||
| Low | 179 (69.7) | 176 (68.5) | ||
| Intermediate - Favorable | 70 (27.2) | 71 (27.6) | ||
| Intermediate - Unfavorable | 5 (2) | 5 (2) | ||
| Unknown | 3 (1.2) | 5 (1.9) | ||
|
| ||||
| Confirmatory Biopsy Characteristics | Median number of cores, (IQR) | 11 (11–11) | 13 (12–14) | <0.001 |
| Median total tumor length, mm (IQR) | 4 (1.5–8.3) | 13.5 (4–21) | <0.001 | |
| Median maximum single core length, mm (IQR) | 3 (1.5–4.8) | 6 (2.5–9) | <0.001 | |
| Median number positive cores, (IQR) | 2 (1–3) | 3 (1–5) | 0.005 | |
| Grade Group, n (%) | <0.001 | |||
| Benign | 97 (37.7) | 32 (12.5) | ||
| 1 | 85 (33.1) | 77 (30.0) | ||
| 2 | 62 (24.1) | 105 (40.9) | ||
| 3 | 8 (3.1) | 27 (10.5) | ||
| 4–5 | 5 (1.9) | 16 (6.2) | ||
| Risk Group (excluding benign biopsies), n (%) | 0.008 | |||
| Low | 76 (47.5) | 74 (32.9) | ||
| Intermediate - Favorable | 65 (40.6) | 98 (43.6) | ||
| Intermediate - Unfavorable | 14 (8.8) | 35 (15.6) | ||
| High | 5 (3.1) | 13 (5.8) | ||
| Unknown | 0 | 5 (2.2) | ||
| Risk Group Change, n (%) | <0.001 | |||
| Increase | 45 (17.5) | 113 (44) | ||
| Decrease | 106 (41.3) | 46 (17.9) | ||
| Equal to initial risk group | 103 (40.1) | 93 (36.2) | ||
IQR = interquartile range
*
MRI-biopsy consisted of MRI-targeted biopsies and systematic biopsies